ReviewHuman vaccines & immunotherapeutics2026
Long-term immune protection after infant hepatitis B vaccination in children.
Review in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hepatitis B virus (HBV) infection in endemic regions often begins in infancy and persists throughout life. Although anti-HBs antibody levels may decline over time, long-term protection usually remains. The me chanisms underlying this sustained protection are not fully understood. Evidence from studies conducted up to 20 ypost-vaccination indicates that booster doses are unnecessary for immunocompetent individuals who completed the full vaccination series as recommended. Therefore, reviewing HBV vaccination studies in children is crucial to update current knowledge on long-term immunity and evaluate the program's strengths and weaknesses. This literature review analyzed studies published from 2013 to 2023 using PubMed, Google Scholar, ScienceDirect, and Scopus databases with relevant keywords. Selection followed PRISMA guidelines. Twenty-seven studies demonstrated protective effects exceeding 10 y, though antibody levels were lower in adolescents. Booster vaccination during adolescence may be beneficial, especially for those born to HBsAg-positive mothers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.